3,667 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Purchased by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. purchased a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 3,667 shares of the company’s stock, valued at approximately $277,000.

A number of other institutional investors also recently made changes to their positions in the company. Nicholas Investment Partners LP boosted its holdings in shares of Vaxcyte by 1.9% during the second quarter. Nicholas Investment Partners LP now owns 87,230 shares of the company’s stock worth $6,587,000 after acquiring an additional 1,586 shares during the period. American Century Companies Inc. boosted its holdings in shares of Vaxcyte by 14.3% during the second quarter. American Century Companies Inc. now owns 527,594 shares of the company’s stock worth $39,839,000 after acquiring an additional 65,870 shares during the period. Quest Partners LLC bought a new stake in shares of Vaxcyte during the second quarter worth approximately $70,000. Arizona State Retirement System boosted its holdings in shares of Vaxcyte by 4.1% during the second quarter. Arizona State Retirement System now owns 25,796 shares of the company’s stock worth $1,948,000 after acquiring an additional 1,013 shares during the period. Finally, Victory Capital Management Inc. boosted its holdings in shares of Vaxcyte by 9.5% during the second quarter. Victory Capital Management Inc. now owns 307,516 shares of the company’s stock worth $23,221,000 after acquiring an additional 26,641 shares during the period. Institutional investors own 96.78% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PCVX. Mizuho boosted their price objective on Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a report on Tuesday, September 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research report on Thursday, June 20th. Bank of America lifted their price target on shares of Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. Needham & Company LLC lifted their price target on shares of Vaxcyte from $95.00 to $140.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Finally, Leerink Partners lifted their price target on shares of Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a research report on Tuesday, September 3rd. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vaxcyte currently has a consensus rating of “Buy” and a consensus price target of $147.50.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, CEO Grant Pickering sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $75.64, for a total transaction of $1,134,600.00. Following the completion of the transaction, the chief executive officer now directly owns 478,888 shares in the company, valued at $36,223,088.32. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Vaxcyte news, COO Jim Wassil sold 3,000 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $76.34, for a total transaction of $229,020.00. Following the sale, the chief operating officer now owns 210,503 shares of the company’s stock, valued at $16,069,799.02. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Grant Pickering sold 15,000 shares of the business’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $75.64, for a total transaction of $1,134,600.00. Following the sale, the chief executive officer now directly owns 478,888 shares in the company, valued at approximately $36,223,088.32. The disclosure for this sale can be found here. Insiders sold a total of 93,283 shares of company stock worth $8,198,738 over the last three months. Corporate insiders own 3.10% of the company’s stock.

Vaxcyte Price Performance

Shares of PCVX opened at $115.18 on Friday. Vaxcyte, Inc. has a one year low of $44.20 and a one year high of $121.06. The company has a market cap of $12.86 billion, a P/E ratio of -26.91 and a beta of 0.97. The firm has a 50 day simple moving average of $89.12 and a two-hundred day simple moving average of $76.38.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($1.10) EPS for the quarter, beating the consensus estimate of ($1.14) by $0.04. During the same quarter last year, the company earned ($0.70) EPS. On average, analysts expect that Vaxcyte, Inc. will post -4.33 earnings per share for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.